Device sales up 8% at Synthelabo
This article was originally published in Clinica
Synthelabo's medical device sales rose 8.3% on a comparable basis in the first half of 1995 to Fr 355 million ($70 million) compared with the same period last year. This includes worldwide sales of Fr 261 million for the company's pacemaker subsidiary, Ela Medical, and Fr 94 million for its surgical catheter division, Porges.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.